Caplin Point Laboratories LimitedNSE: CAPLIPOINT

Press Release May 12 2023

Caplin Point Laboratories Limited has informed the Exchange regarding a press release dated May 12, 2023, titled "Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT), has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ketorolac Tromethamine Injection USP.".

View Attachment